Webinar
Spatial Biomarker Panels for Clinical Trials
Spatial Biomarker Panels for Clinical Trials
Mar 18, 2026
1 pm EST | 10 am PST
Most immuno-oncology drugs work by altering the tumor microenvironment to recruit and activate immune cells. To understand how these drugs work and how patients respond, researchers need the spatial context of several biomarkers—typically 8 to 18—to see how cells interact within the tumor. Traditional multiplex immunofluorescence (mIF) methods can’t capture this complexity at scale.
Through a case study and technology walk-through, this webinar highlights the barriers that have been broken in mIF that now enable flexible development of high performance high-plex biomarker panels, and application of those panels at the scale necessary for deriving valuable quantitative spatial insights from large cohort clinical trials.
Speaker
Jennifer Bordeaux, PhD
Associate Director, Digital Pathology Services
Navigate Biopharma Services, Inc.
Jennifer Bordeaux, Ph.D. is a strategic leader with over a decade of industry experience in digital pathology. As Associate Director of Digital Pathology Solutions at Navigate Biopharma Services, she leads a team of scientists driving the adoption of multiplexed fluorescence immunochemistry assays to support clinical trial programs. Her expertise spans assay development, image analysis, and biomarker validation, with a strong focus on operational efficiency and scientific innovation. Jennifer earned her Ph.D. in Experimental Pathology from Yale University, where her research centered on biomarker validation in breast cancer using AQUA technology. She is a published author and frequent presenter in the field of quantitative pathology.
Speaker
Tad George, PhD
Senior VP, Biology R&D
RareCyte Inc.
Tad has over 15 years of startup experience dedicated to creating scientific markets for novel instrumentation platforms that span basic research, drug discovery and clinical applications. Prior to joining RareCyte, Tad has held similar positions at Biodesy, Inc. and DVS Sciences, and was Director of Biology at Amnis Corporation. Tad completed his B.A. in Biochemistry from the Univ. of Texas at Austin, Ph.D. in Immunology from UT Southwestern Medical Center at Dallas, and post-doctoral training at Immunex Corp. in Seattle.